Abstract
The Novel Nonsteroidal and Selective Mineralocorticoid Receptor Antagonist Finerenone Differentiates from SGLT2 Inhibitor Empagliflozin by Anti-Fibrotic Effects in a Progressive Mouse Kidney Fibrosis Model
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
